{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:04:11Z","timestamp":1793988251630,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.eururo.2018.10.014","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T23:39:24Z","timestamp":1539992364000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models"],"prefix":"10.1016","volume":"75","author":[{"given":"Marcus M.","family":"Ilg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Stebbeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uros","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nim","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Cellek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.10.014_bib0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.10.014_bib0215","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1038\/sj.ijir.3901081","article-title":"History, epidemiology, and clinical presentation of Peyronie's disease","volume":"15","author":"Hellstrom","year":"2003","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.eururo.2018.10.014_bib0220","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.10.014_bib0225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1756287214537331","article-title":"Experience in the use of collagenase Clostridium histolyticum in the management of Peyronie's disease: current data and future prospects","volume":"6","author":"Egui Rojo","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0230","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1464-410x.2001.02176.x","article-title":"The Nesbit operation for Peyronie's disease: an analysis of the failures","volume":"87","author":"Andrews","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.10.014_bib0235","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biocel.2006.11.005","article-title":"Fibroblasts and myofibroblasts: their source, function and role in disease","volume":"39","author":"McAnulty","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0240","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0245","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbadis.2012.09.014","article-title":"Cytokine mediated tissue fibrosis","volume":"1832","author":"Borthwick","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.eururo.2018.10.014_bib0250","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-4889(91)90066-7","article-title":"The effect of transforming growth factor \u03b2 on rates of procollagen synthesis and degradation in vitro","volume":"1091","author":"McAnulty","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.eururo.2018.10.014_bib0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biocel.2005.08.021","article-title":"Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved","volume":"38","author":"Guyot","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1513\/pats.200602-021TK","article-title":"Targeting genes for treatment in idiopathic pulmonary fibrosis. Challenges and opportunities, promises and pitfalls","volume":"3","author":"Ask","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.eururo.2018.10.014_bib0265","first-page":"334","article-title":"Molecular mechanism in renal fibrosis\u2014a review","volume":"6","author":"Nandhini","year":"2014","journal-title":"J Pharm Sci Res"},{"key":"10.1016\/j.eururo.2018.10.014_bib0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11934-004-0074-y","article-title":"New discoveries in the basic science understanding of Peyronie's disease","volume":"5","author":"Jalkut","year":"2004","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2018.10.014_bib0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jsm.12760","article-title":"The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets","volume":"12","author":"Gelfand","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.10.014_bib0280","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1073\/pnas.1702750114","article-title":"Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis","volume":"114","author":"Bollong","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2018.10.014_bib0285","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jsxm.2018.05.003","article-title":"Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie's disease","volume":"15","author":"Mateus","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.10.014_bib0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2008.10.003","article-title":"Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring","volume":"28","author":"Fisher","year":"2009","journal-title":"Matrix Biol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0295","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","article-title":"An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression","volume":"158","author":"El-Sakka","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0300","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0022-5347(05)67616-1","article-title":"A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression","volume":"163","author":"Bivalacqua","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0305","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1073\/pnas.76.3.1274","article-title":"Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro","volume":"76","author":"Bell","year":"1979","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.eururo.2018.10.014_bib0310","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1524-475X.2008.00392.x","article-title":"A review of fibroblast-populated collagen lattices","volume":"16","author":"Dallon","year":"2008","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.eururo.2018.10.014_bib0315","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","article-title":"L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente","year":"2003","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.eururo.2018.10.014_bib0320","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease","volume":"97","author":"Ferrini","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.10.014_bib0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0330","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1096\/fj.201700249R","article-title":"Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in MDX mice with Duchenne muscular dystrophy","volume":"31","author":"Nio","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.eururo.2018.10.014_bib0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11684-014-0378-3","article-title":"Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor \u03b2-induced Smad signaling","volume":"8","author":"Gong","year":"2014","journal-title":"Front Med"},{"key":"10.1016\/j.eururo.2018.10.014_bib0340","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/ndt\/gfu240","article-title":"Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor \u03b1-mediated transforming growth factor-\u03b21\/Smad signaling pathway","volume":"29","author":"Kim","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eururo.2018.10.014_bib0345","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1478-3231.2008.01811.x","article-title":"Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis","volume":"29","author":"Ryu","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.eururo.2018.10.014_bib0350","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/jcp.25049","article-title":"Tamoxifen inhibits TGF-\u03b2-mediated activation of myofibroblasts by blocking non-Smad signaling through ERK1\/2","volume":"230","author":"Carthy","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0355","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/jsre.2001.6350","article-title":"Tamoxifen decreases fibroblast function and downregulates TGF\u03b22 in Dupuytren's affected palmar fascia","volume":"103","author":"Kuhn","year":"2002","journal-title":"J Surg Res"},{"key":"10.1016\/j.eururo.2018.10.014_bib0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1054\/bjps.1997.0100","article-title":"Topical tamoxifen\u2014a potential therapeutic regime in treating excessive dermal scarring?","volume":"51","author":"Hu","year":"1998","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.eururo.2018.10.014_bib0365","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/ijmm.2015.2288","article-title":"Estradiol attenuates the TGF-\u03b21-induced conversion of primary TAFs into myofibroblasts and inhibits collagen production and myofibroblast contraction by modulating the Smad and Rho\/ROCK signaling pathways","volume":"36","author":"Jiang","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.eururo.2018.10.014_bib0370","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie's disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0375","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0380","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell\u2019Atti","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2018.10.014_bib0385","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Irish J Med Sci"},{"key":"10.1016\/j.eururo.2018.10.014_bib0390","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park","year":"2016","journal-title":"World J Mens Health"},{"key":"10.1016\/j.eururo.2018.10.014_bib0395","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie's disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0400","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.10.014_bib0405","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.12346","article-title":"Deformity stabilization and improvement in men with untreated Peyronie's disease","volume":"113","author":"Berookhim","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.10.014_bib0410","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4103\/1008-682X.126395","article-title":"Solving a bottleneck in animal models of Peyronie's disease","volume":"16","author":"Stebbeds","year":"2014","journal-title":"Asian J Androl"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818307553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818307553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:54:35Z","timestamp":1775249675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818307553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0302283818307553"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.10.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734273270.793574531","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}